Shoreline Biosciences Raises $43 Million to Develop New Cancer Treatments

By Bruce Harpham Sunday, April 18, 2021

Shoreline Biosciences has raised $43 million in funding from investors to advance its cancer treatments. The San Diego biotech startup company develops cell-based treatments for patients. The business was founded in 2020.

3D rendering of a DNA molecule forming in a test tube.

Investors Supporting the Business

Early investors in the biotechnology startup include Boxer Capital, BVF Partners, Cormorant Capital, Janus Henderson Investors, and Logos Capital.

"We look to invest in companies that are pushing the boundaries of scientific innovation, and Shoreline is doing exactly that. Their approach to intelligently designing iPSC-derived cell therapies will help solve many of the current challenges with cell therapies," said Christopher Fuglesang, Managing Director of Boxer Capital. Based in San Diego, the investment fund focuses on biotechnology company investments. The Boxer Capital investment portfolio includes PassageBio, Rocket Pharma, and Syndax. Christopher Fuglesang has also joined the Board of Directors.

Induced Pluripotent Stem Cells (iPS) are developed from skin or blood cells. The first human iPS were created in 2007 by researchers at UCLA's Broad Stem Cell Research Center. These cells can be "reprogrammed" into various purposes like liver cells, blood cells, active motor neurons, and beyond.

Shoreline Biosciences With UC San Diego Lab

Shoreline Biosciences is avoiding the complexity of building its lab facilities. Instead, the startup has a partnership with the Advanced Cell Therapy Laboratory of UC San Diego. The San Diego lab facility includes classrooms, clean rooms, incubators, and nitrogen storage freezers. Experts lead the lab in cell therapy, regenerative medicine, and quality assurance. Shoreline Biosciences has not disclosed the cost of working with the UC San Diego lab.

The Stem Cell Business Is Worth Billions

The US stem cell business is worth $2.7 billion, according to a ReportLinker report released in September 2020. Outside of the United States (US), the stem cell industry is going even faster. In China, the stem cell market is forecasted to reach $2.6 billion by 2027, nearly the same size as the US market in 2020.

Major companies in the stem cell startup include Bone Therapeutics (a company trading under the stock ticker EBR: BOTHE), Neuralstem (a biotechnology company based in Maryland working on central nervous system stem cells), US Stem Cell (a biotechnology company based in Florida). Beyond smaller companies, large corporations like Sangamo Therapeutics and Vericel, both listed on the NASDAQ stock exchange, are also active in the stem cell business.

The Founders Behind Shoreline Biosciences

The biotechnology business is led by a team of co-founders. Steve Holtzman, a co-founder of the startup company, has a long history in the biotech business. From 2001 to 2011, he was the founder and CEO of Infinity Pharmaceuticals. Dan S. Kaufman, who holds MD and Ph.D. degrees, is also a co-founder of the biotechnology company. In addition to his work at the startup company, Kaufman is also a professor in the department of medicine at UC San Diego. William Sandborn has held several medical positions in organizations such as the Mayo Clinic and UC San Diego. He has also published more than 700 articles in publications such as Nature, the Lancet, and the New England Journal of Medicine. Kleanthis G. Xanthopoulos, co-founder and executive chairman of Shoreline Biosciences, has founded five companies and holds a Ph.D. in molecular biology from the University of Stockholm.

About the Author


Headshot for author Bruce Harpham

Bruce Harpham is an author and marketing consultant based in Canada. His first book "Project Managers At Work" shared real-world success lessons from NASA, Google, and other organizations. His articles have been published in CIO.com, InfoWorld, Canadian Business, and other organizations. Visit BruceHarpham.com for articles, interviews with tech leaders, and updates on future books.

Related Articles